A5022951811- Malaria Research and Control
- Mosquito-borne diseases and control
- Hepatitis B Virus Studies
- Complement system in diseases
- vaccines and immunoinformatics approaches
- Viral Infections and Vectors
- Herpesvirus Infections and Treatments
- Bacteriophages and microbial interactions
- Vibrio bacteria research studies
- Streptococcal Infections and Treatments
- Rabies epidemiology and control
- Antibiotic Resistance in Bacteria
- Virus-based gene therapy research
- Poxvirus research and outbreaks
- Bacterial Genetics and Biotechnology
- Escherichia coli research studies
- Molecular Sensors and Ion Detection
- Dengue and Mosquito Control Research
- HIV Research and Treatment
- Aquaculture disease management and microbiota
- Invertebrate Immune Response Mechanisms
- Heavy Metal Exposure and Toxicity
- Microbial infections and disease research
- Hepatitis C virus research
- Parasites and Host Interactions
SUNY Upstate Medical University
2019-2024
Walter Reed Army Institute of Research
1996-2016
Malaria Consortium
2007
GlaxoSmithKline (Belgium)
2007
Reprogenetics
1996
Selma University
1990
Background This Phase 1/2a study evaluated the safety, immunogenicity, and efficacy of an experimental malaria vaccine comprised recombinant Plasmodium falciparum protein apical membrane antigen-1 (AMA-1) representing 3D7 allele formulated with either AS01B or AS02A Adjuvant Systems. Methodology/Principal Findings After a preliminary safety evaluation low dose AMA-1/AS01B (10 µg/0.5 mL) in 5 adults, 30 malaria-naïve adults were randomly allocated to receive full (50 (n = 15) AMA-1/AS02A 15),...
Background A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both reduce the morbidity this parasite as a key component in efforts eradicate malaria worldwide. Vivax protein 1 (VMP001), novel chimeric that incorporates amino- carboxy- terminal regions of circumsporozoite (CSP) truncated repeat region contains sequences from VK210 (type 1) VK247 2) parasites, was developed candidate for global use. Methods We conducted first-in-human Phase dose escalation study...
ABSTRACT The RTS,S/AS02A protein-based vaccine consistently demonstrates significant protection against infection with Plasmodium falciparum malaria and also clinical severe disease in children areas of endemicity. Here we demonstrate rhesus macaques that priming a replication-defective human adenovirus serotype 35 (Ad35) vector encoding circumsporozoite protein (CS) (Ad35.CS), followed by boosting RTS,S an improved MPL- QS21-based adjuvant formulation, AS01B, maintains antibody responses...
The highly attenuated NYVAC vaccinia virus strain has been utilized to develop a multiantigen, multistage vaccine candidate for malaria, disease that remains serious global health problem and which no effective exists. Genes encoding seven Plasmodium falciparum antigens derived from the sporozoite (circumsporozoite protein surface 2), liver (liver stage antigen 1), blood (merozoite 1, serine repeat antigen, apical membrane sexual (25-kDa sexual-stage antigen) stages of parasite life cycle...
ABSTRACT The apical membrane antigen 1 (AMA1) has emerged as a promising vaccine candidate against malaria. Advanced evaluation of its protective efficacy in humans requires the production highly purified and correctly folded protein. We describe here process for expression, fermentation, refolding, purification recombinant ectodomain AMA1 (amino acids 83 Gly to 531 Glu ) Plasmodium falciparum (3D7) produced Escherichia coli. A synthetic gene containing an E. coli codon bias was cloned into...
Dengue virus (DENV) infections are major causes of morbidity and mortality throughout the tropics subtropics. More than 400 million estimated to occur every year, resulting in nearly 100 symptomatic more 20,000 deaths. Early immune response kinetics infection remain unclear, large part due variable incubation period exhibited by DENVs after introduction into a susceptible host. To fill this knowledge gap, we performed comprehensive virologic immunologic analysis individuals experimentally...
A successful vaccine against Plasmodium vivax malaria would significantly improve the health and quality of lives more than 1 billion people around world. subunit is only option in absence long-term culture P. parasites. The circumsporozoite protein that covers surface sporozoites one best-studied malarial antigens most promising clinical trials. We report here development a novel "immunologically optimal" recombinant expressed Escherichia coli encodes chimeric CS encompassing repeats from...
Antibodies against apical membrane antigen 1 (AMA-1) of Plasmodium falciparum inhibit merozoite invasion into erythrocytes. Invasion-inhibitory polyclonal AMA-1 antibodies secondary proteolytic processing and surface redistribution on merozoites. We present evidence supporting inhibition as probable causes by antibodies. Polyclonal anti-AMA-1 was much more inhibitory than monoclonal antibody (MAb) 4G2dc1 in an assay. Although both immunoglobulin G (IgG) inhibited the 66-kDa form AMA-1, only...
Plasmodium falciparum liver-stage antigen 1 (LSA-1) is expressed solely in infected hepatocytes and thought to have a role liver schizogony merozoite release. Specific humoral, cellular, cytokine immune responses LSA-1 are well documented, with epitopes identified that correlate antibody production, proliferative T-cell responses, or induction. With the goal of developing vaccine against this preerythrocyte-stage protein, we undertook good manufacturing practices (GMP) manufacture...
Abstract Background The development of an asexual blood stage vaccine against Plasmodium falciparum malaria based on the major merozoite surface protein-1 (MSP1) antigen is founded protective efficacy observed in preclinical studies and induction invasion growth inhibitory antibody responses. 42 kDa C-terminus MSP1 has been developed as recombinant protein antigen, 3D7 allotype, formulated with Adjuvant System AS02A, evaluated extensively human clinical trials. In rabbit studies, FVO allele...
Dengue human infection models (DHIM) have been used as a safe means to test the viability of prophylaxis and therapeutics.A phase 1 study 12 healthy adult volunteers using challenge virus, DENV-1-LVHC strain 45AZ5, was performed. A dose escalating design determine safety performance profile virus. Subjects were evaluated extensively until 28 days then out 6 months.Twelve subjects received virus: with 0.5 mL 6.5 × 103 plaque-forming units (PFU)/mL (low-dose group) 104 PFU/mL (mid-dose group)....
ABSTRACT The Plasmodium vivax merozoite surface protein 1 (MSP-1) 42-kDa fragment (PvMSP-1 p42) is a promising vaccine candidate antigen against the blood stage of malarial parasite. We have developed process for production this target, keeping in mind its use human volunteers. A novel strain, Origami(DE3), Escherichia coli with mutations glutathione and thioredoxin reductase genes yielded 60% more soluble PvMSP-1 p42 than conventional E. BL21(DE3) strain. Recombinant was purified to ≥99%...
The 42-kDa fragment of the merozoite surface protein 1 (MSP-1(42)) is a leading candidate for development vaccine to control malaria. We previously reported method production Plasmodium vivax MSP-1(42) (PvMSP-1(42)) as soluble (S. Dutta, L. W. Ware, A. Barbosa, C. F. Ockenhouse, and D. E. Lanar, Infect. Immun. 69:5464-5470, 2001). report here process manufacture same PvMSP-1(42) but an insoluble inclusion body-derived which was then refolded in vitro. compared immunogenicity protective...
ABSTRACT Several lines of evidence suggest that targeting pre-erythrocytic-stage parasites for malaria vaccine development can provide sterile immunity. The objectives this study were (i) to evaluate preclinically the safety and immunogenicity a new recombinant antigen, liver-stage antigen 1 (LSA1), in nonhuman primates; (ii) investigate potential immune interference between LSA1 leading candidate, RTS,S, by comparing responses after single-antigen vaccination simultaneous administration...
NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) were evaluated in Plasmodium berghei rodent malaria model system. Immunization of mice with a CSP recombinant elicited high level protection (60 to 100%). Protection did not correlate CS repeat-specific antibody responses and was abrogated by vivo CD8+ T-cell depletion. enhanced modification subcellular localization CSP. These results suggest potential poxvirus-based vectors for development vaccine...
The apical membrane antigen 1 of Plasmodium falciparum is one the leading candidate antigens being developed as a vaccine to prevent malaria. This merozoite transmembrane protein has an ectodomain that can be divided into three subdomains (D I, D II, and III). We have previously expressed major portion this shown it induce antibodies invasion red blood cells in vitro growth assay. To analyze antibody responses directed against individual subdomains, we constructed six different genes express...